Tempest Therapeutics Inc TPST released new and updated results from the planned data analysis of an ongoing Phase 1b/2 study of TPST-1120 in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).
TPST-1120 shows clinical superiority in multiple study endpoints when combined with atezolizumab and bevacizumab (triplet arm) in a randomized comparison to atezolizumab and bevacizumab.
The confirmed objective response rate (cORR or confirmed ORR) was 30% for the TPST-1120 triplet arm versus 13.3% for the atezolizumab + bevacizumab control arm.
The duration of response (DoR) has not yet been reached.
The progression-free survival (PFS) was a median of 7 months for the TPST-1120 arm versus 4.27 months for the control arm; HR of 0.7 favors the TPST-1120 arm and is not yet mature.
Median overall survival not reached for the TPST-1120 arm (10.84 months, NE) versus 15.1 months (7.49 months, NE) for the control arm; HR 0.59 favors the TPST-1120 arm and is not yet mature.
40% of the patients in the TPST-1120 arm were on treatment (16/40) compared to 16.7% in the atezolizumab + bevacizumab control arm (5/30).
TPST-1120 remains well tolerated, with safety data comparable between the two arms.
Price Actions: TPST shares are up 800.40% at $2.16 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.